Skip to content
Portage BioTech, LLC.
Portage BioTech, LLC.Portage BioTech, LLC.
  • about us
    • overview
    • leadership
  • our portfolio
    • PORT-2 & PORT-3 – iNKT agonists
    • PORT-1 – Intratumoral Amphiphilic Formulations
    • PORT-4 – Nanolipogel Formulations
    • PORT-5 – STING Agonist with VLP Delivery
  • news
  • investors / media
    • investor home
    • stock information
    • company information and policies
    • financial and regulatory reports
    • shareholder circular
    • details of key advisors
    • press releases
  • contact
  • about us
    • overview
    • leadership
  • our portfolio
    • PORT-2 & PORT-3 – iNKT agonists
    • PORT-1 – Intratumoral Amphiphilic Formulations
    • PORT-4 – Nanolipogel Formulations
    • PORT-5 – STING Agonist with VLP Delivery
  • news
  • investors / media
    • investor home
    • stock information
    • company information and policies
    • financial and regulatory reports
    • shareholder circular
    • details of key advisors
    • press releases
  • contact

Category Archives: Media Coverage

Portage Biotech Begins Phase I Trial of Invariant Natural Killer T-Cell Therapy

Media CoverageBy walidApril 8, 2021
...

How to Find the Right Partner

Media CoverageBy walidApril 5, 2021
...

Juvenescence CEO reveals why its deal with Portage is the smart choice for its longevity IP portfolio

Media CoverageBy walidMarch 9, 2021
...

CEO Ian Walters Discusses Expectations for Portage Biotech (PRTG) Pipeline

Media CoverageBy walidMarch 3, 2021
...

Portage Biotech to begin trading its shares on the Nasdaq February 25th

Media CoverageBy walidFebruary 22, 2021
...

CEO Spotlight: Portage Biotech CEO Dr. Ian Walters Talks Asset Pipeline, Uplist, and Strategic Initiatives in a $20 Billion Sector

Media CoverageBy walidDecember 1, 2020
...
Copyright © All rights reserved Portage Biotech, Inc

terms of use   privacy policy   disclaimer

Go to Top